Jupiter Asset Management Ltd. Purchases 91,683 Shares of Adaptive Biotechnologies Corporation $ADPT

Jupiter Asset Management Ltd. grew its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 33.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 362,811 shares of the company’s stock after acquiring an additional 91,683 shares during the period. Jupiter Asset Management Ltd.’s holdings in Adaptive Biotechnologies were worth $5,892,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Intech Investment Management LLC increased its position in shares of Adaptive Biotechnologies by 10.6% during the fourth quarter. Intech Investment Management LLC now owns 64,391 shares of the company’s stock valued at $1,046,000 after buying an additional 6,155 shares during the period. Geode Capital Management LLC increased its position in shares of Adaptive Biotechnologies by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after buying an additional 110,825 shares during the period. Clearstead Advisors LLC increased its position in shares of Adaptive Biotechnologies by 1,545.6% during the fourth quarter. Clearstead Advisors LLC now owns 3,752 shares of the company’s stock valued at $61,000 after buying an additional 3,524 shares during the period. Legal & General Group Plc increased its position in shares of Adaptive Biotechnologies by 47.4% during the fourth quarter. Legal & General Group Plc now owns 362,381 shares of the company’s stock valued at $5,885,000 after buying an additional 116,454 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after buying an additional 1,565 shares during the period. 99.17% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ADPT shares. JPMorgan Chase & Co. decreased their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Morgan Stanley decreased their price target on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. TD Cowen upped their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average target price of $19.57.

Adaptive Biotechnologies Trading Down 0.3%

ADPT stock opened at $15.15 on Friday. The company’s 50 day moving average is $13.92 and its 200 day moving average is $15.55. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of -45.91 and a beta of 2.16. Adaptive Biotechnologies Corporation has a 1-year low of $9.05 and a 1-year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. The company had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. Adaptive Biotechnologies’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.20) earnings per share. As a group, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.48 EPS for the current fiscal year.

Insider Buying and Selling

In other Adaptive Biotechnologies news, COO Julie Rubinstein sold 141,583 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07. Following the completion of the sale, the chief operating officer owned 516,610 shares of the company’s stock, valued at $6,865,746.90. This represents a 21.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Chad M. Robins sold 470,167 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total value of $6,192,099.39. Following the completion of the sale, the chief executive officer directly owned 2,301,113 shares of the company’s stock, valued at approximately $30,305,658.21. This represents a 16.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,237,392 shares of company stock valued at $31,269,192 in the last 90 days. 5.70% of the stock is owned by company insiders.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.